Join our daily newsletter At The Bell to receive exclusive market insights
- Biopharmaceutical company Dimerix (DXB) doses its first patients with its inflammatory disease treatment, DMX-200, in India
- The company is currently studying its DMX-200 as a potential new treatment for respiratory complications associated with COVID-19 in India and Australia
- Patient recruitment followed both regulatory and ethics approvals in India required to commence the study
- An initial safety analysis is planned after the first 80 patients recruited in India in the 600-patient study, which is expected to occur in the first quarter of 2022
- On the market this morning, Dimerix is up 1.89 per cent and trading at $0.27 per share
Dimerix (DXB) has had its first patients dosed in DMX-200 COVID-19 CLARITY 2.0 study in India.
The company is currently studying its DMX-200 product as a potential new treatment for respiratory complications associated with COVID-19 in India and Australia.
Patient recruitment followed both regulatory and ethics approvals in India required to commence the study.
An initial safety analysis is planned after the first 80 patients recruited in India in the 600-patient study, which is expected to occur in the first quarter of 2022.
“Any new treatment for COVID-19 respiratory complications will be very much welcomed by patients, their families and the medical community,” said Professor Vivekanand Jha, Principal Investigator and Executive Director at the George Institute India.
“Inflammatory disease treatments such as DMX-200 hold significant potential to improve
clinical response, survival and quality of life post treatment, and we are looking forward to
investigating this drug in patients.”
During the last week, the World Health Organisation reported a 71 per cent weekly increase in case numbers globally.
In India, in the previous week, case numbers have surged, ranging from an 8 per cent to a 1212 per cent increase in case numbers in individual states, including a 585 per cent increase in cases in Chhattisgarh where the first patients have been recruited to the Clarity study.
On the market this morning, Dimerix was up 1.89 per cent and is trading at $0.27 per share at 10:57 am AEDT.
